Gen-Probe/DiagnoCure plan gene test for prostate cancer
This article was originally published in Clinica
Executive Summary
Gen-Probe has paid $3m upfront and promised additional payments and royalties to Canadian diagnostics firm DiagnoCure in return for exclusive rights to a genetic test for prostate cancer.